Download PDF
Thromb Haemost 1985; 53(01): 105-109
DOI: 10.1055/s-0038-1661246
Original Article
Schattauer GmbH Stuttgart

Enhanced Platelet Release Reaction, Shortened Platelet Survival Time and Increased Platelet Aggregation and Plasma Thromboxane B2 in Chronic Obstructive Arterial Disease

J Zahavi
The Department of Medicine, Day Clinic and the Vascular Laboratory, Tel-Aviv Medical Center, Tel-Aviv, Israel
,
M Zahavi
The Department of Medicine, Day Clinic and the Vascular Laboratory, Tel-Aviv Medical Center, Tel-Aviv, Israel
› Author Affiliations
Further Information

Publication History

Received 02 July 1984

Accepted 23 November 1984

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Plasma β-thromboglobulin (βTG) and thromboxane B2 (TXB2) level, platelet aggregation (PA) in platelet rich plasma, platelet survival time using luIndium radiolabelled platelets and platelet sensitivity to prostacyclin (PGI2) were measured in chronic obstructive arterial disease (COAD) patients. Severity of the disease was assessed by the ankle pressure index using Doppler auscultation.

Platelet survival time was shorter, plasma βTG and TXB2 and the rate and extent of PA induced by ADP or 1-epinephrine (but not collagen) were greater in the patients than in controls. βTG was inversly correlated with the pressure index and positively with TXB2 indicating increased platelet TXA2 synthesis. Platelet sensitivity to PGI2 was similar in the patients and controls.

These results indicate increased platelet consumption and enhanced in vivo platelet activation and PA in COAD. The enhanced activation correlates with the severity of the disease and the activated platelets presumably synthesize increased amounts of TXA2. It is therefore concluded that platelets might be involved in the pathogenesis of COAD. The normal platelet sensitivity to PGI2 suggests that the administration of the compound may improve the abnormal platelet function in COAD patients and may attenuate the progression of the disease.

Key words

Peripheral vascular disease - Platelet aggregation - TXB2 - β-thromboglobulin - PGI2
 

  • References

  • 1 Jurgens JL, Barker NW, Hines Jr EA. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognos-tic factors. Circulation 1960; 21: 185-188
    PubMedGoogle Scholar
  • 2 Jorgensen L, Packham MA, Roswell HC, Mustard JF. Deposition of formed elements of blood on the intima and signs of intimal injury in the aorta of rabbit, pig, and man. Lab Invest 1972; 27: 341-350
    PubMedGoogle Scholar
  • 3 Fuster V. Role of platelets in the development of atherosclerotic disease and possible interference with platelet inhibitor drugs. Scand J Haematol 1981; Suppl (Suppl. 38) 1-33
    PubMedGoogle Scholar
  • 4 Prathap P. The morphology of two-year old platelet-rich thrombi in femoral arteries of normocholesteremic monkeys. Light and electron- microscopic observations J Pathol 1973; 110: 145-151
    CrossrefPubMedGoogle Scholar
  • 5 Holmsen H. Biochemistry of the platelet release reaction. In Biochemistry and Pharmacology of Platelets, Ciba Foundation Symposium, 35. Elsevier; North Holland: Biomedical Press; Amsterdam: 1975. pp 175-205
    Google Scholar
  • 6 Pepper DS. Macromolecules released from platelet storage organelles. Thromb Haemostas 1979; 42: 1667-1672
    PubMedGoogle Scholar
  • 7 Marcus AJ. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res 1978; 19: 793-826
    PubMedGoogle Scholar
  • 8 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 420-425
    CrossrefPubMedGoogle Scholar
  • 9 Moncada S, Vane JR. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978; 34: 129-135
    CrossrefPubMedGoogle Scholar
  • 10 Harker LA, Schwartz SM, Ross R. Endothelium and arteriosclerosis. Clin Haematol 1981; 10: 283-296
    PubMedGoogle Scholar
  • 11 De Gaetano G. Platelets, prostaglandins and thrombotic disorders. Clin Haematol 1981; 10: 297-326
    PubMedGoogle Scholar
  • 12 Dreyfuss F, Zahavi J. Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease. Athero-sclerosis 1973; 17: 107-112
    CrossrefPubMedGoogle Scholar
  • 13 Zahavi J, Betteridge JD, Jones NA G, Galton DJ, Kakkar VV. Enhanced in-vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-64
    CrossrefPubMedGoogle Scholar
  • 14 Mehta P, Mehta J. Platelet function studies in coronary heart disease: decreased platelet sensitivity to PGI2 in patients with myocardial infarction. Thromb Res 1980; 18: 273-277
    CrossrefPubMedGoogle Scholar
  • 15 Davi G, Rini GB, Averna S. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent diabetes mellitus. Thromb Res 1982; 26: 359-370
    CrossrefPubMedGoogle Scholar
  • 16 Tremoli E, Colli S, Madema P, Baraldi A, Gianfrancheschi G, Nicosia S. Platelet PGI2 interaction and lipoproteins: studies on platelet aggregation and adenylate cyclase activity in normal and hypercholes- teremic subjects. Thromb Haemostas 1983; 50: 286 (Abstr)
    PubMedGoogle Scholar
  • 17 D’Angelo V, Villa S, Mysliwiec M, Donati MB, de Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemostas 1978; 39: 535-536
    PubMedGoogle Scholar
  • 18 Zahavi J, Kakkar VV. β-Thromboglobulin - a specific marker of invivo platelet release reaction. Thromb Haemostas 1980; 44: 23-29
    PubMedGoogle Scholar
  • 19 Davis HH, Heaton WA, Siegel BA, Mathias CJ, Joist JH, Sherman LA, Welch MJ. Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by Indium-111 labelled autologous platelets. Lancet 1978; 1: 1185-1187
    PubMedGoogle Scholar
  • 20 Celia G, Zahavi J, de HaasH, Kakkar VV. β-Thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1978; 43: 127-136
    PubMedGoogle Scholar
  • 21 Scherer R, Siess W, Weber PC. Radioimmunological and biological measurement of prostaglandins in rabbit urine. Prostaglandins 1977; 13: 1127-1139
    CrossrefPubMedGoogle Scholar
  • 22 Siegel S. Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill Kogakusha, Ltd; Tokyo: 1983
    Google Scholar
  • 23 Karpatkin S. Human platelet senescence. Ann Rev Med 1972; 23: 101-123
    CrossrefPubMedGoogle Scholar
  • 24 Betteridge DJ, Zahavi J, Jones NA G, Shine B, Kakkar VV, Galton DJ. Platelet function in diabetes mellitus in relationship to complications, glycosylated haemoglobin and serum lipoproteins. Eur J Clin Invest 1981; 11: 273-277
    CrossrefPubMedGoogle Scholar
  • 25 Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased plasma thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87-96
    PubMedGoogle Scholar
  • 26 Lagarde M, Burtin M, Berciaud P, Blanc M, Velardo B, Dechavanne M. Increase of platelet thromboxane A2 formation of its plasmatic half-life in diabetes mellitus. Thromb Res 1980; 19: 823-830
    CrossrefPubMedGoogle Scholar
  • 27 Szczeklik A, Gryglewski RJ, Musial J, Grodzinska L, Serwonska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
    PubMedGoogle Scholar
  • 28 Neri Semeri GG, Gensini GF, Masotti G, Abbate R, Laureano R, Poggesi L. Prostaglandins in ischemic heart disease. Agressologie 1982; 23: 69-73
    PubMedGoogle Scholar
  • 29 Lewy RI, Smith JB, Silver MJ, Saia J, Walinsky P, Wiener L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal’s angina. Prostaglandins Med 1979; 2: 243-248
    CrossrefPubMedGoogle Scholar
  • 30 Moncada S. Prostacyclin and thromboxane A2 in the regulation of platelet-vascular interactions. In Hemostasis, Prostaglandins and Renal Disease. Remuzzi G, Mecca G, de Gaetano G. (Eds) Raven Press; New York: 1980. pp 175-188
    Google Scholar
  • 31 Maseri A, L’Abbate A, Baroldi G, Chierchia S, Marzilli M, Ballettra AM, Severi S, Parodi O, Biagini A, Distante A, Pesola A. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of “preinfarction” angina N Engl J Med 1978; 299: 1271-1277
    CrossrefPubMedGoogle Scholar
  • 32 Van Oost BA, Veldhuyzen BF E, Van Houwelingen HC, Timmermans AP M, Sixma JJ. Tests for platelet changes, acute phase reactants and serum lipids in diabetes mellitus and peripheral vascular disease. Thromb Haemostas 1982; 48: 289-293
    PubMedGoogle Scholar
  • 33 Bernstein EF, Froneck A. Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 1982; 62: 473-487
    CrossrefPubMedGoogle Scholar
  • 34 Carter SA. Response of ankle systolic pressure to leg exercise in mild or questionable arterial disease. N Engl J Med 1972; 287: 578-582
    CrossrefPubMedGoogle Scholar
  • 35 Dean RH, Yao JS T, Stanton PE, Bergan JJ. Prognostic indications in femoropopliteal reconstructions. Arch Surg 1975; 110: 1287-1293
    CrossrefPubMedGoogle Scholar
  • 36 Corson JD, Johnson WE, Logerfo FW, Bush HL, Menzoian JO, Kumaki DJ, Nasbeth DC. Doppler ankle systolic pressure. Prognostic value in vein bypass grafts of the lower extremity Arch Surg 1978; 113: 932-935
    CrossrefPubMedGoogle Scholar
  • 37 Preston FE, Ward JD, Marcola BH, Porter NR, Timperly WR, O’Malley BC. Elevated β-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet 1978; 1: 238-239
    PubMedGoogle Scholar
  • 38 Matthews JH, O’Connor JF, Heamshaw JR, Wood JK. Beta- thromboglobulin and glycosylated haemoglobin in diabetes mellitus. Scand J Haematol 1979; 23: 421-426
    PubMedGoogle Scholar
  • 39 Zahavi J, Betteridge DJ, Jones NA G, Leyton J, Galton DJ, Kakkar VV. Enhanced in-vivo platelet release reaction in diabetic patients with retinopathy. In Vascular Occlusion: Epidemiological, Pathophysiological and Therapeutic Aspects. Tesi M, Dormandy J. (Eds) Academic Press; London - New York: 1981. pp 171-177
    Google Scholar
  • 40 Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease, The Framingham Study. Ann Intern Med 1971; 74: 1-12
    CrossrefPubMedGoogle Scholar
  • 41 Zahavi M, Zahavi J. Enhanced platelet release reaction, shortened platelet survival time, increased platelet aggregation and plasma thromboxane B2 level in chronic obstructive arterial disease. Abstracts of the International Congress on Platelets, Prostaglandins and Cardiovascular System. Florence, Italy: 02/1984. no C45
    Google Scholar
  • 42 Zahavi J, Dreyfuss F. An abnormal pattern of adenosine diphosphate- induced platelet aggregation in acute myocardial infarction. Thrombos Diathes Haemorrh 1969; 21: 76-88
    PubMedGoogle Scholar
  • 43 Zahavi J. Role of platelets in myocardial infarction, ischemic heart disease, cerebrovascular disease, thromboembolic disorders and acute idiopathic pericarditis. Thromb Haemostas 1977; 38: 1073-1084
    PubMedGoogle Scholar
  • 44 Kwaan HC, Colwell JA, Cruz S, Suwanwella N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-246
    PubMedGoogle Scholar
  • 45 Carvalho AC A, Colman RW, Less RS. Platelet function in hyperbetalipoproteinemia. N Engl J Med 1974; 290: 434-438
    CrossrefPubMedGoogle Scholar
  • 46 Bradby GV H, Valente AJ, Walton KW. Serum lipoproteins in peripheral vascular disease. Lancet 1978; 2: 1271-1274
    PubMedGoogle Scholar
  • 47 Szczeklik A, Skawinski A, Gluszko P, Nizankowski R, Szczeklik J, Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979; 1: 1111-1114
    PubMedGoogle Scholar
  • 48 Hossman V, Heinen A, Auel H, Fitzgerald GA. A randomized placebo-controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb Res 1981; 22: 481-490
    CrossrefPubMedGoogle Scholar